Qiagen (NYSE:QGEN) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Qiagen (NYSE:QGEN) posted its quarterly earnings results on Wednesday. The company reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.60 by $0.02, Zacks reports. Qiagen had a net margin of 19.16% and a return on equity of 14.40%. The company had revenue of $535.00 million for the quarter, compared to analysts’ expectations of $527.50 million. During the same quarter in the previous year, the firm posted $0.60 EPS. Qiagen’s revenue was up .2% on a year-over-year basis. Qiagen updated its FY 2026 guidance to 2.430- EPS.

Qiagen Stock Down 0.9%

QGEN stock opened at $41.93 on Thursday. The stock has a 50-day simple moving average of $39.21 and a two-hundred day simple moving average of $41.73. Qiagen has a twelve month low of $32.53 and a twelve month high of $57.81. The firm has a market capitalization of $8.64 billion, a PE ratio of 21.90, a PEG ratio of 4.22 and a beta of 0.63. The company has a quick ratio of 2.57, a current ratio of 3.21 and a debt-to-equity ratio of 0.49.

Qiagen Increases Dividend

The business also recently announced an annual dividend, which was paid on Tuesday, July 14th. Shareholders of record on Tuesday, July 7th were issued a dividend of $0.35 per share. This represents a yield of 90.0%. The ex-dividend date of this dividend was Tuesday, July 7th. This is a boost from Qiagen’s previous annual dividend of $0.26. Qiagen’s payout ratio is presently 18.32%.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Zacks Research raised shares of Qiagen from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 29th. Barclays set a $38.00 target price on shares of Qiagen and gave the stock an “equal weight” rating in a research report on Wednesday, April 29th. JPMorgan Chase & Co. lowered their price target on shares of Qiagen from $60.00 to $45.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 29th. Kepler Capital Markets set a $38.60 price target on shares of Qiagen and gave the company a “hold” rating in a research report on Thursday, June 25th. Finally, Stifel Nicolaus set a $36.00 price target on shares of Qiagen and gave the company a “hold” rating in a research note on Monday, May 18th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Qiagen presently has a consensus rating of “Hold” and a consensus target price of $43.34.

Hedge Funds Weigh In On Qiagen

Several hedge funds have recently bought and sold shares of QGEN. Price T Rowe Associates Inc. MD increased its holdings in Qiagen by 12.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 8,429,424 shares of the company’s stock worth $379,072,000 after acquiring an additional 906,589 shares during the period. Amundi boosted its holdings in Qiagen by 4.4% in the 3rd quarter. Amundi now owns 4,290,273 shares of the company’s stock valued at $201,471,000 after purchasing an additional 181,509 shares during the period. Boston Partners bought a new position in Qiagen in the 3rd quarter valued at $179,450,000. Sei Investments Co. grew its position in shares of Qiagen by 5.0% during the 3rd quarter. Sei Investments Co. now owns 1,902,296 shares of the company’s stock valued at $84,995,000 after purchasing an additional 90,294 shares in the last quarter. Finally, Barclays PLC grew its position in shares of Qiagen by 41.7% during the 4th quarter. Barclays PLC now owns 1,539,762 shares of the company’s stock valued at $69,243,000 after purchasing an additional 452,831 shares in the last quarter. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library?preparation kits and proteomics solutions.